Your browser doesn't support javascript.
loading
Preoperative Plasma Insulin-Like Growth Factor-I and Its Binding Proteins-Based Risk Stratification of Patients Treated With Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Kardoust Parizi, Mehdi; Rouprêt, Morgan; Singla, Nirmish; Teoh, Jeremy Yuen-Chun; Chlosta, Piotr; Babjuk, Marek; Abufaraj, Mohammad; Margulis, Vitaly; D'Andrea, David; Klemm, Jakob; Matsukawa, Akihiro; Laukhtina, Ekaterina; Fazekas, Tamas; Karakiewicz, Pierre I; Bhanvadia, Raj; Gontero, Paolo; Shariat, Shahrokh F.
Afiliación
  • Kardoust Parizi M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Rouprêt M; Department of Urology, Pitié Salpêtrière Hospital, AP-HP, GRC 5, Predictive Onco-Urology, Sorbonne University, Paris, France.
  • Singla N; Departement of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD.
  • Teoh JY; Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Chlosta P; Department of Urology, Jagiellonian University, Cracow, Poland.
  • Babjuk M; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Abufaraj M; Department of Special Surgery, Division of Urology, The University of Jordan, Amman, Jordan.
  • Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • D'Andrea D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Klemm J; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Matsukawa A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
  • Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Fazekas T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary.
  • Karakiewicz PI; Departement of Urology, Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Bhanvadia R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Gontero P; Department of Surgical Sciences, Division of Urology, Torino School of Medicine, Turin, Italy.
  • Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Special Surgery, Division of Urology, The University of Jordan, Amman, Jordan; Department of
Clin Genitourin Cancer ; 22(6): 102133, 2024 Jun 04.
Article en En | MEDLINE | ID: mdl-38945766
ABSTRACT

INTRODUCTION:

We evaluate the predictive and prognostic value of insulin-like growth factor-I (IGF-1), IGF binding protein-2 (IGFBP-2) and -3 (IGFBP-3) in patients treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).

METHODS:

This is a retrospective analysis of a multi-institutional database comprising 753 patients who underwent RNU for UTUC and had a preoperative plasma available. Logistic and Cox regression analyses were performed. The discriminative ability and clinical utility of the models was calculated using the lasso regression test, area under receiver operating characteristics curves, C-index, and decision curve analysis (DCA).

RESULTS:

Lower preoperative plasma levels of IGFBP-2 and -3 independently correlated with increased risks of lymph node metastasis, pT3/4 disease, nonorgan confined disease, and worse recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) (all P ≤ .004). The addition of both IGFBP-2 and -3 to a postoperative multivariable model, that included standard clinicopathologic characteristics, improved the model's concordance index by 10%, 9%, and 8% for RFS, CSS, and OS, respectively. On DCA, addition of both IGFBP-2 and -3 to base models improved their performance for RFS, CSS, and OS by a statistically and clinically significant margin. Plasma IGF-1 was not associated with any of outcomes.

CONCLUSIONS:

We confirmed that a lower plasma levels of IGFBP-2 and -3 both are independent and clinically significant predictors of adverse pathological features and survival outcomes in UTUC patients treated with RNU. These findings might help guide the clinical decision-making regarding perioperative systemic therapy and follow-up scheduling.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Irán